Clinical Trial

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
It is intended to examine the efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-05-28
Trial Details
NCT Number NCT06925360
Lead Sponsor International Peace Maternity and Child Health Hospital
Conditions Bronchopulmonary Dysplasia
Enrollment 20 participants
Start Date 2025-04-12
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27